Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WestGene Biopharma Completes $21 Million Funding for mRNA Drugs

publication date: Dec 8, 2022

Chengdu WestGene Biopharma completed a $21 million Series A Round to advance its portfolio of nearly 20 mRNA candidates, including its lead COVID-19 vaccine, which is in IND stage. The company was founded in mid-2021 by a team of academicians from West China Hospital of Sichuan University. WestGene's mRNA pipeline consists of mRNA drugs, vaccine adjuvants and novel adjuvants including anti-infection vaccines, tumor vaccines, anti-aging vaccines, obesity treatments, pulmonary fibrosis treatments and gene editing for rare/genetic diseases. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital